Events & Presentations
Date | Event Details | Remind Me |
---|---|---|
Feb 4, 2021 4:30 PM EST
|
Arrowhead Pharmaceuticals 2021 First Quarter Results
|
Date | Event Details |
---|---|
Nov 25, 2019 4:30 PM EST
|
Arrowhead Pharmaceuticals 2019 Year End Results
Prepared Remarks 191.4 KB
|
Nov 18, 2019
|
American Heart Association Scientific Sessions 2019
Philadelphia
November 18, 9:32 a.m. EST – Dr. Christie Ballantyne, Baylor Coll Med, Houston, TX, will deliver an oral presentation titled, “RNA Interference Targeting Apolipoprotein C-III Results in Deep and Prolonged Reductions in Plasma Triglycerides” November 18, 9:38 a.m. EST – Dr. Gerald Watts, Univ of Western Australia, Royal Perth Hosp, Perth, Australia, will deliver an oral presentation titled, “RNA Interference Targeting Hepatic Angiopoietin-Like Protein 3 Results in Prolonged Reductions in Plasma Triglycerides and LDL-C in Human Subjects” |
Nov 8 - Nov 12, 2019
|
The Liver Meeting® 2019, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
Boston
Dose Response with the RNA Interference Therapy JNJ-3989 Combined with Nucleos(t)ide Analogue Treatment in Expanded Cohorts of Patients with Chronic Hepatitis B
FIRST CLINICAL EXPERIENCE WITH RNA INTERFERENCE [RNAi]-BASED TRIPLE COMBINATION THERAPY IN CHRONIC HEPATITIS B (CHB): JNJ-73763989 (JNJ-3989), JNJ-56136379 (JNJ-6379) AND A NUCLEOS(T)IDE ANALOGUE (NA)
|
Oct 31, 2019 11:15 AM CDT
|
North American Cystic Fibrosis Conference
View Presentation 1.6 MB
Nashville
Erik Bush, Ph.D., Arrowhead’s vice president of extra-hepatic targeting, will deliver a poster presentation titled, “Therapeutic Inhibition of ENaC With a Lung-Targeted RNAi Molecule Delivery Platform Preserves Normal Mucus Clearance in a Mucostatic Sheep Model of Cystic Fibrosis”
|
Oct 28, 2019 2:30 PM EDT
|
DIA/FDA Oligonucleotide-Based Therapeutics Conference
View Presentation 2.5 MB
North Bethesda, MD
James Hamilton, M.D., Arrowhead’s vice president of clinical development, will deliver an oral presentation titled, “The emerging safety and activity of siRNA drugs using the TRIMTM platform”
|
Oct 18, 2019 8:00 AM EDT
|
Arrowhead Analyst R&D Day 2019
View Presentation 40.1 MB
New York, NY
|
Oct 7, 2019 1:30 PM EDT
|
Chardan 3rd Annual Genetic Medicines Conference
New York, NY
Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, will participate in a fireside chat presentation with Keay Nakae, CFA, Chardan senior research analyst
|
Oct 4, 2019 10:05 AM EDT
|
2019 Cantor Global Healthcare Conference
New York, NY
Vince Anzalone, CFA, Arrowhead’s vice president of investor relations, will participate in a fireside chat presentation with Elemer Piros, Ph.D., Cantor Fitzgerald biotechnology equity research analyst
|
Sep 20, 2019 4:15 PM CEST
|
Molecular Therapies for Liver Disease in Alpha-1 Antitrypsin Deficiency
View Presentation 10.5 MB
Naples, Italy
|
Sep 16, 2019 11:00 AM +04
|
Global Summit On Cardiology & Heart Diseases
View Presentation 5.6 MB
Dubai, UAE
Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, will deliver a keynote presentation titled, “Treating hypertriglyceridemic states with RNA interference – emergence of an exciting new modality to treat cardiovascular diseases”
|